Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CitruSlim is a proprietary dietary supplement formulated for weight management and metabolic health. It is a standardized blend of Citrus bergamia (bergamot) extract and Eurycoma longifolia (commonly known as tongkat ali), marketed as containing citrus flavanone-O-glycosides and other bioactive plant compounds. The supplement’s mechanism of action involves several pathways: - Activation of AMP-activated protein kinase (AMPK), the body’s master regulator of energy metabolism, which encourages fat burning over storage. - Modulation of hunger hormones, specifically reducing ghrelin (“hunger hormone”) and leptin (“satiety hormone”), to help control appetite. - Reduction in cortisol levels, thereby supporting stress management and potentially breaking the cycle of stress-induced eating. Clinical studies have shown that CitruSlim can significantly reduce body mass index (BMI) in overweight or obese individuals compared to placebo, with additional effects on lowering cortisol, cholesterol, triglycerides, and blood glucose[2][5][7]. The product is caffeine-free and 100% plant-based.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CitruSlim.